This story was corrected on April 17. One patient had >50 copies/ML. We regret the error.
By Marie Rosenthal, MS
Results from a phase 2 clinical study evaluating the investigational oral combination of islatravir (ISL; Merck) and lenacapavir (LEN; Sunlenca, Gilead) showed the combination maintained a high rate of viral suppression at 24 weeks, when given once weekly, according to Amy Colson, MD, PhD, who presented the data at CROI 2024.
“Weekly oral regimens have the potential to